Hugh Rogers, CEO and Director of XPhyto Therapeutics Corp. (CSE: XPHY) (OTC:XPHYF), recently appeared on Gamechangers LIVE, a podcast series hosted by Sergio Tigera, putting a spotlight on individuals who are gamechangers in their fields and sharing perspective on their journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. During the podcast, Rogers discussed the company’s various lines of business, including its work to scale industrial production of pharmaceutical-grade psychedelics. “The psychedelic space is really exciting. This is absolutely the cutting edge of mental health treatment for everything – depression, anxiety, trauma-related counseling, PTSD, addiction treatment. The preliminary data looks extremely promising.” “We have a few of these projects on the go. In Germany, it’s psilocybin. In Canada, right now we’re working on the industrial GMP production of pharmaceutical-grade mescaline. The government is relatively liberal. Actually, internationally, the Canadian government is at the absolute forefront. People are probably familiar with mescaline from the peyote cactus. It’s relatively common, but not easy to scale up to agricultural production.” Throughout the interview, Rogers discusses the company’s competitive advantage, how XPhyto Therapeutics chooses projects to work on and where he expects the company to be in five to 10 years.
Jorge A. Plasencia is co-founder, chairman, and CEO of Republica Havas, one of America’s leading creative, media, and communications agencies. Since launching the agency in 2006, he has provided strategic, […]